A Phase 3, Randomized, Active-controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Given With DTaP Compared to Open-label DTaP in Healthy Japanese Infants.

Trial Profile

A Phase 3, Randomized, Active-controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Given With DTaP Compared to Open-label DTaP in Healthy Japanese Infants.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2015

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; DTaP vaccine; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Diphtheria; Pertussis; Pneumococcal infections; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Feb 2012 Actual patient number added 551 according to ClinicalTrials.gov.
    • 13 Feb 2012 Actual end date (November 2011) added as reported by ClinicalTrials.gov.
    • 13 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top